Dental Care After Chemotherapy

Common Oral Effects of Chemotherapy

Chemotherapy can leave a range of oral changes, some short-term, some long-term:

Mucositis. Painful inflammation of the oral lining is common during active chemotherapy. Most patients recover after treatment, but some develop chronic sensitivity or recurrent sores.

Taste alteration. Most patients experience changes in taste during chemotherapy. Many recover within months, though some have persistent changes. See taste and swallowing disorders.

Reduced saliva. Some chemotherapy regimens cause dry mouth, often less severe than radiation-induced dryness but still significant.

Weakened tooth structure. Long courses of chemotherapy, particularly in pediatric and adolescent patients, can affect tooth development and enamel quality, leading to fragile or sensitive teeth.

Gum sensitivity and bleeding. Many patients have ongoing gum sensitivity that can persist for months or longer.

Increased decay risk. Combined dry mouth, dietary changes during treatment, and altered oral microbiology can accelerate cavity formation.

Risk from related medications. Many cancer patients also receive bisphosphonates (Zometa, Reclast), denosumab (Xgeva, Prolia), or anti-angiogenic drugs to manage bone metastases or other complications. These medications carry independent risk for osteonecrosis of the jaw (MRONJ/BRONJ) that follows the patient long after chemotherapy ends.

What Specialized Care Looks Like

Dental care after chemotherapy involves a few key elements:

Comprehensive review of treatment history. Type of chemotherapy, regimens used, total duration, and any concurrent medications all factor into our planning. Bisphosphonate or denosumab exposure is particularly important to identify, as it changes our approach to extractions and other procedures.

Restoration of weakened teeth. Crowns, bridges, and veneers for teeth that have become brittle, sensitive, or chipped. Patients who finished chemotherapy as children or teenagers may have specific dental developmental issues that require restorative care.

Management of dry mouth. Saliva substitutes, prescription stimulants, custom fluoride trays, and dietary guidance.

Frequent monitoring. Maintenance every 3 to 4 months for high-risk survivors, every 6 months for those at lower risk, with attention to early decay and gum issues.

Careful surgical planning. For patients on or recently on bone-modifying drugs, every extraction and implant decision is made with osteonecrosis risk in mind. We coordinate with oncology when needed.

Dental implants when appropriate. Most chemotherapy survivors are good candidates for dental implants, particularly those without bone-modifying drug history.

A Note on Bisphosphonates and Denosumab

If you have ever received bisphosphonates (Zometa, Reclast, Aredia, Bonefos), denosumab (Xgeva, Prolia), or related drugs, even years ago, this affects how dental care should be approached. The risk of medication-related osteonecrosis of the jaw is real and persists long after the medication is discontinued.

Before any extraction, implant, or oral surgery, a dental oncologist should be involved in the planning. Many general dentists are unfamiliar with the specific risks and protocols. We are.

Pediatric and Young Adult Survivors

Survivors who received chemotherapy as children or adolescents often have unique dental concerns: delayed or abnormal tooth development, undersized teeth, missing teeth, weakened enamel, or jaw growth differences. We work with these patients to plan appropriate restorations as they reach adulthood, sometimes including implants when growth is complete.